Interaction between Nevirapine and Artesunate
Moderate
Antagonism
| ID | DDInter1285 and DDInter122 |
| Interaction | Coadministration with nevirapine may decrease the peak plasma concentration (Cmax) and systemic exposure (AUC) of dihydroartemisinin (DHA), an active metabolite of artesunate. The mechanism is unknown. Reduced efficacy of artesunate may occur. |
| Management | The potential for diminished pharmacologic effects of artesunate should be considered during coadministration with nevirapine. Alternative treatments may be required if an interaction is suspected. |
| References | |
| Alternative for Nevirapine |
J05A
More
|
| Alternative for Artesunate |
P01B
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.